Based on an analysis of withdrawn drugs that gained approval through the FDA's fast-track program, Columbia researchers argue that such programs have positively contributed to drug development.
A new mouse model may be critical for understanding the most aggressive types of pancreatic cancer and finding ways to prevent its growth and recurrence.
Studies exploring metformin’s power to prevent prostate cancer progression have been inconclusive. Columbia research now shows that the drug has promise, but only for specific patients.
Columbia bioengineers are the first to program bacteria that guide immune cells to tumors, which could make more cancers treatable with immunotherapies.
The association between neighborhood walkability and obesity-related cancers was stronger among women living in neighborhoods with higher levels of poverty.
Physician-scientist Neil Vasan brings the perspectives he's gained from classical singing and structural biology to his search for new breast cancer treatments.
Biomedical engineer Santiago Correa uses his expertise in nanotechnology to create injectable biomaterials that reprogram the body’s immune system to fight cancer, autoimmune disease, and infection.